// App-Quantinova.ai

273 : The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy

Researchers

Presenter

  • Margaret M. Parker

Principal Investigators

  • Catherine Tcheandjieu

  • David Erbe

  • Emre Aldinc

  • Philip N. Hawkins

  • Julian Gillmore

  • Leland E. Hull

  • Julie A. Lynch

  • Jacob Joseph

  • Simina Ticau

  • Alexander O. Flynn-Carroll

  • Aimee M. Deaton

  • Lucas D. Ward

  • Themistocles L. Assimes

  • Philip S. Tsao

  • Kyong-Mi Chang

  • Daniel J. Rader

  • Kevin Fitzgerald

  • Akshay K. Vaishnaw

  • Gregory Hinkle

  • Paul Nioi

Medical Centers

  • Merrimack Pharmaceuticals, Cambridge, MA

  • University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA

  • Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA Stanford University School of Medicine, Stanford, CA

  • Ctr for Amyloidosis and Acute Phase Proteins, London, United Kingdom

  • Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MAMassachusetts General Hospital, Boston, MA

  • VA Salt Lake City Health Care System, Salt Lake City, UTUniversity of Massachusetts, Boston, MA

  • Medicine Departments, VA Boston Healthcare System, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • University of Pennsylvania, Philadelphia, PA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Familial Amyloid Polyneuropathy

  • Familial carpal tunnel syndrome

  • Peripheral neuropathy

  • Heart muscle disease

  • Congestive heart failure

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved